Home
>
US Stocks
>
CRISPR Therapeutics AG
CRISPR Therapeutics AG
CRSP

CRISPR Therapeutics AG

$96.9920.43%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
99.24
Today Low/High
96.78 / 99.24
52 Week Low/High
$76.71 / $220.2
P/E ratio
20.57
Market Cap
$9.19B

Company Details

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
Organisation
CRISPR Therapeutics AG
Headquaters
Zug, Zug, Switzerland
Employees
410
Industry
Health Technology
CEO
Samarth Kulkarni

Discover more

Frequently Asked Questions

What is CRISPR Therapeutics AG share price today

Can Indians buy CRISPR Therapeutics AG shares?

How can I buy CRISPR Therapeutics AG shares from India?

Can Fractional shares of CRISPR Therapeutics AG be purchased?

What are the documents required to start investing in CRISPR Therapeutics AG stocks?

We are a SEBI registered investement advisor